Susan Lin

Enopace Biomedical Ltd. develops medical devices to treat heart failure patients. The firm's technology consists of a minimally invasive, implantable neurostimulation device that increases cardiac efficiency by reducing left ventricular workload and improves the systolic/diastolic ratio. The company was by Yossi Gross and Amir Dagan in 2008 and is headquartered in Caesarea, Israel.

Enopace Biomedical Ltd. develops medical devices to treat heart failure patients. The firm's technology consists of a minimally invasive, implantable neurostimulation device that increases cardiac efficiency by reducing left ventricular workload and improves the systolic/diastolic ratio. The company was by Yossi Gross and Amir Dagan in 2008 and is headquartered in Caesarea, Israel.

Enopace Biomedical Ltd. develops medical devices to treat heart failure patients. The firm's technology consists of a minimally invasive, implantable neurostimulation device that increases cardiac efficiency by reducing left ventricular workload and improves the systolic/diastolic ratio. The company was by Yossi Gross and Amir Dagan in 2008 and is headquartered in Caesarea, Israel.

Enopace Biomedical Ltd. develops medical devices to treat heart failure patients. The firm's technology consists of a minimally invasive, implantable neurostimulation device that increases cardiac efficiency by reducing left ventricular workload and improves the systolic/diastolic ratio. The company was by Yossi Gross and Amir Dagan in 2008 and is headquartered in Caesarea, Israel.

Enopace Biomedical Ltd. develops medical devices to treat heart failure patients. The firm's technology consists of a minimally invasive, implantable neurostimulation device that increases cardiac efficiency by reducing left ventricular workload and improves the systolic/diastolic ratio. The company was by Yossi Gross and Amir Dagan in 2008 and is headquartered in Caesarea, Israel.